New combo aims to tame a dangerous leukemia
NCT ID NCT07187505
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether adding venetoclax to the standard two-drug treatment (ATRA and arsenic trioxide) can improve outcomes for people newly diagnosed with acute promyelocytic leukemia (APL) who have very high white blood cell counts. APL is a rare blood cancer, and high white blood cells raise the risk of early death. The trial will enroll 28 patients and track early deaths, complications, and how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road
Hefei, Anhui, 230022, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a pill that helps leukemia cells die), all-trans retinoic acid (ATRA), and arsenic trioxide (ATO)
What this could lead to
If it works, this combination could lower the risk of early death and improve treatment success for APL patients with dangerously high white blood cell counts.
What could go wrong
This is a small, early-phase study with only 28 participants and no comparison group, so results may not apply broadly. Adding venetoclax could also increase side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.